Secondary Prevention of Cardiovascular Disease in the Elderly Trial
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of a polypill strategy containing
aspirin (100 mg), ramipril (2.5, 5 or 10 mgs), and atorvastatin (40 mgs) compared with the
standard of care (usual care according to the local clinical practices at each participating
country) in secondary prevention of major cardiovascular events (cardiovascular death,
nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent revascularization) in
elderly patients with a recent myocardial infarction.
Phase:
Phase 3
Details
Lead Sponsor:
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Collaborators:
Centre Hospitalier Universitaire de Besancon Charite University, Berlin, Germany Ferrer Internacional S.A. General University Hospital, Prague Istituto Di Ricerche Farmacologiche Mario Negri London School of Hygiene and Tropical Medicine Semmelweis University Servicio Madrileño de Salud, Madrid, Spain Wroclaw Medical University